B and T lymphocyte attenuator expression in mature B cell lymphomas

Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russel JH, Allison JP, Murphy KM (2003) BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4:670–679

Riley JL, June CH (2005) The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 105:13–21

Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehevari Z, Shimizu J, Takahashi T, Nomura T (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8–27

Vendel AC, Calemine-Fenaux J, Izrael-Tomasevic A, Chauhan V, Arnott D, Eaton DL (2009) B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J Immunol 182:1509–1517

Han P, Goularte OD, Rufner K, Wilkinson B, Kaye J (2004) An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocytes positive selection. J Immunol 172:5931–5939

Hurchla MA, Sedy JR, Gavrieli M, Drake CG, Murphy TL, Murphy KM (2005) B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T cells. J Immunol 174:3377–3385

Compaan DM, Gonzalez LC, Tom I, Loyet KM, Eaton D, Hymowitz SG (2005) Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex. J Biol Chem 280:39553–39561

Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Coleman L, Hildner K, Scheu S, Pfeffer K, Ware CF, Murphy TL, Murphy KM (2005) B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 6:90–98

M'Hidi H, Thibult ML, Chetaille B, Rey F, Bouadallah R, Nicollas R, Olive D, Xerri L (2009) High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Am J Clin Pathol 132:589–596

Gonzalez LC, Loyet KM, Calemine-Fenaux J, Chauhan V, Wranik B, Ouyang W, Eaton DL (2005) A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. PNAS 102(4):1116–1121

Hobo W, Norde WJ, Schaap N, Fredrix H, Maas F, Schellens K, Falkenburg JHF, Korman AJ, Olive D, van der Voort R, Dolstra H (2012) B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation. J Immunol 189(1):39–49

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon

Krieg C, Han P, Stone R, Goularte OD, Kaye J (2005) Functional analysis of B and T lymphocyte attenuator engagement on CD4+ and CD8+ T cells. J Immunol 175:6420–6427

Tao R, Wang L, Murphy KM, Fraser CC, Hancock WW (2008) Regulatory T cell expression of herpes virus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J Immunol 180:6649–6655

Steinberg MW, Turovskaya O, Shaikh RB, Kim G, McCole DF, Pfeffer K, Murphy KM, Ware CF, Kronenberg M (2008) A crucial role for HVEM and BTLA in preventing intestinal inflammation. J Exp Med 205(6):1463–1476

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511

Iwata A, Watanabe N, Oya Y, Owada T, Ikeda K, Suto A, Kagami S, Hirose K, Kanari H, Kawashima S, Nakayama T, Taniguchi M, Iwamoto I, Nakajima H (2010) Protective roles of B and T lymphocyte attenuator in NKT cell-mediated experimental hepatitis. J Immunol 184:127–133

Oki M, Watanabe N, Owada T, Oya Y, Ikeda K, Saito Y, Matsamura R, Seto Y, Iwamoto I, Nakajima H (2011) A functional polymorphism in B and T lymphocyte attenuator is associated with susceptibility to rheumatoid arthritis. Clin Dev Immunol. doi: 10.1155/2011/305656

Hervé M, Xu K, Ng Y-S, Wardemann H, Albesiano E, Messmer BT, Chiorazzi N, Meffre E (2005) Unmutated and mutated chronic lymphocytic leukemias derives from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 15:1636–1643

Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA (2009) B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cells migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 114(5):1029–1037

Xerri L, Chetaille B, Seriari N, Atias C, Guillaume Y, Arnoulet C, Olive D (2008) Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Human Pathol 39:1050–1058

Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM (2012) CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 72:1–10

Norde WI, Hobo W, van der Voort R, Dolstra H (2012) Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood 120(4):728–736

Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Julie Vose J, Armitage JO, Smeland EB, Kvaloy S, Harald Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159–2169

Lejeune M, Alvaro T (2009) Clinicobiological prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma. Haematologica 94(1):16–21

De Jong D, Koster A, Hagenbeek A, Raemaekers J, Veldhuizen D, Heisterkamp S (2009) Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 94(1):70–77

Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, van Laar R, van Krieken JH, Baars JW, Raemaekers J, Kluin PM, van't Veer LJ, de Jong D (2007) Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25:390–398

Derré L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE (2010) BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 120(1):157–167

Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114:3367–3375

Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA (2008) SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111:2230–223